Prometic Annual General Meeting

May 8, 2013 at 10:30 am ET


Pierre Laurin, B.Sc.Pharm., M.Sc.
President & Chief Executive Officer
ProMetic Life Sciences Inc.

Mr. Pierre Laurin has over 25 years of experience in the pharmaceutical and biotechnology industry. Involved in the development of ProMetic's platform technology since 1989, Mr. Laurin founded ProMetic Life Sciences Inc. in 1994. As Chairman and CEO of the Company since its inception, he took the Company public on the Toronto Stock Exchange and has since raised over $95 million through equity financings and multinational funding. Mr. Laurin’s corporate development achievements include the successful close of some 20 licensing agreements and joint venture agreements with multinationals including the American Red Cross, Merck, and Arriva Pharmaceuticals.

Bruce Pritchard, BA, CA, MloD
Chief Financial Officer
ProMetic Life Sciences Inc.

Prior to his nomination as Chief Financial Officer of the ProMetic Group, Mr. Bruce Pritchard was formerly Chief Financial Officer of the U.K. affiliate ProMetic BioSciences Ltd (PBL). Mr. Pritchard is a Chartered Accountant with many years of experience in corporate accountancy including senior finance positions with biotech and pharmaceutical companies. Mr. Pritchard has a proven track record of success in strategic acquisitions and raising finance from public and private sources. Mr. Pritchard is currently Chairman of the Institute of Chartered Accountants of Scotland’s England & Wales Area Committee and is a Trustee and Non-Executive Director of The Scottish Global Health Foundation.

Mr. Pritchard is a graduate of Heriot-Watt University where he gained a BA in Accountancy and Computer Science in 1993. He qualified as a Member of the Institute of Chartered Accountants of Scotland in 1996.

The following information is required to view this webcast.
Please complete all of the information to continue.

Email *
First Name *
Last Name *
Company *

About ProMetic

ProMetic is a global biopharmaceutical company offering technologies for large-scale drug purification, drug development, proteomics (the study of proteins), and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission of bringing to market effective, innovative, lower cost products for the treatment of hematological and nephrological disorders and cancer. Headquartered in Montréal (Canada), ProMetic has R&D facilities in the UK, the USA and Canada, manufacturing facilities in the UK and business development activities in the USA, Europe, Asia and in the Middle-East. ProMetic focuses its activities in the Protein Technologies and Therapeutics markets.

The Bottom Line

CO2 emissions saved by using gowebcasting viewing this webcast:

Share this page on: